The main patent on Advair (fluticasone+salmeterol ... aiming to become the first drug for asthma that can be dosed twice a year.

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Do not initiate Advair HFA with acutely deteriorating asthma; use in this setting is ... and of concomitant disease or other drug therapy. In addition, as with other products containing beta ...

Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...

and Hikma and partner Vectura require a further trial to get their drug past the FDA. Approved in asthma and chronic obstructive pulmonary disease (COPD), Advair is a combination of the long ...

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates ...

Also Read: Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca’s Asthma Drug On Efficacy, Analysts Say Treatment with Tezspire significantly reduced nasal polyp severity: the Nasal ...